Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

NCT05651828 | Recruiting Early Phase 1 DMC FDA Drug

• 1 other identifier: MCC 21997
• Study Type: interventional
• Target: 34
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to compare how well tolerated and effective four different dosing schedules (two personalized, intermittent dosing schedules as compared to a fixed intermittent and continuous dosing regimen) work in people with advanced basal cell carcinoma.

Conditions

Advanced Basal Cell Carcinoma

Keywords

Skin cancer

Outcome Measures

Primary Outcomes (1)

• Time to Treatment Failure

  Time to treatment failure (defined as the time from the day of first dose of study drug to the first day of treatment with another regiment or with the same regimen in a non-adaptive fashion) or a personalized vs fixed intermittent vs continuous dosing of vismodegib.

  Up to 36 months

Secondary Outcomes (1)

• Overall Response Rate

  Up to 36 months

Study Arms (4)

A: Continuous Vismodegib

ACTIVE COMPARATOR

Participants will receive continuous 150 mg by mouth daily vismodegib as per commercially available package insert.

Drug: Vismodegib 150 MG Oral Capsule

Arm B: Fixed Intermittent Vismodegib

EXPERIMENTAL

Participants will receive intermittent 150 mg dose vismodegib by mouth with a 12 weeks on/8 weeks off regimen. Participants will take vismodegib for first 12 weeks, then off 8 weeks, and alternate in fixed cycles.

Drug: Vismodegib 150 MG Oral Capsule

Arm C: Personalized Intermittent Vismodegib (Adaptive)

EXPERIMENTAL

Participants will start with an 8-week run in period with vismodegib 150 mg dose by mouth daily. Participants will take vismodegib for the first 8 weeks, then start personalized dosing based on specific model.

Drug: Vismodegib 150 MG Oral Capsule

Arm D: Personalized Intermittent Vismodegib (TGI model)

EXPERIMENTAL

Participants will start with an 8-week run in period with vismodegib 150 mg dose by mouth daily. Participants will take vismodegib for the first 8 weeks, then start personalized dosing based on TGI model.

Drug: Vismodegib 150 MG Oral Capsule

Interventions

Vismodegib 150 MG Oral Capsule DRUG

Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.

Also known as: Erivedge

A: Continuous Vismodegib; Arm B: Fixed Intermittent Vismodegib; Arm C: Personalized Intermittent Vismodegib (Adaptive); Arm D: Personalized Intermittent Vismodegib (TGI model)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with a cytologically or histologically confirmed locally advanced basal cell carcinoma. (Nodal involvement permitted)
• Adult males or females 18 years of age or older at time of signing informed consent. All races and ethnicities are eligible, and no upper limit of age is specified.
• Must have ability to comprehend and the willingness to sign written informed consent for study participation.
• Patients must have at least one cutaneous tumor site amenable to direct and accurate measurement by ruler/calipers.
• Patients may have received prior hedgehog inhibitor therapy (if more than 6 months prior) or other systemic treatments for basal cell carcinoma in the past.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤2
• Agreement not to donate blood or blood products during the study and for 24 months after discontinuation of vismodegib.
• Patients must have adequate hepatic, renal, and bone marrow function as defined in the protocol.
• Participants must have a negative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for ≥1 year.
• Women of reproductive potential are required to use two forms of acceptable contraception (including one acceptable barrier method with spermicide) during therapy and for 24 months after completing therapy.
• Female patients must agree not to become pregnant or donate lactation during treatment and until 24 months after stop of treatment. Male patients must use condoms at all times, even after a vasectomy, during sexual intercourse with female partners of reproductive potential during treatment with vismodegib and for 3 months after the last dose to avoid exposing a pregnant partner and unborn fetus to vismodegib. Male patients must agree not to donate sperm during the study and for 3 months after discontinuation of vismodegib.

You may not qualify if:

• Received prior hedgehog inhibitor therapy in the last 6 months
• Female patients who are pregnant, intend to become pregnant or are nursing.
• Uncontrolled intercurrent illness including, but not limited to, serious infection. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.
• Inability or unwillingness to swallow capsules.
• Any known allergy, hypersensitivity or severe reaction to vismodegib or any of the ingredients
• Co-treatment with a statin or St. John's Wort.

Sponsors & Collaborators

• H. Lee Moffitt Cancer Center and Research Institute: lead
• Genentech, Inc.: collaborator

Study Sites (1)

Moffitt Cancer Center

Tampa, Florida, 33617, United States

RECRUITING

Related Links

• Moffitt Cancer Center Clinical Trials website

MeSH Terms

Conditions

Skin Neoplasms

Interventions

HhAntag691

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Zeynep Eroglu, MD

  Moffitt Cancer Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Sy Olson-Mcpeek

CONTACT

813-745-0935; sy.olson-mcpeek@moffitt.org

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 7, 2022
• First Posted: December 15, 2022
• Study Start: March 23, 2023
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): December 1, 2029
• Last Updated: April 1, 2026

Record last verified: 2026-03

Locations

US (1)